FUTURE RECTAL CANCER DIAGNOSTICS

– a method with the potential to generate significant health economic benefits

FUTURE RECTAL CANCER DIAGNOSTICS

– a method with the potential to generate significant health economic benefits

Reports (SV)

Words from the CEO

2024-10-24
Reports (SV)

Words from the CEO

2024-10-24

Latest news from NanoEcho

Skärmavbild 2024-10-25 kl. 14.07.04
Watch the live broadcast of the Q3 presentation, hosted by G&W Fondkommission
Skärmavbild 2024-10-24 kl. 08.55.44
CEO Linda Persson summarises the third quarter
Skärmavbild 2024-10-16 kl. 12.57.31
Today the recruitment of study participants in NanoEcho's clinical study begins!

Latest news from NanoEcho

Skärmavbild 2024-10-25 kl. 14.07.04
Watch the live broadcast of the Q3 presentation, hosted by G&W Fondkommission
Skärmavbild 2024-10-24 kl. 08.55.44
CEO Linda Persson summarises the third quarter

NanoEcho in summary

In a short time, NanoEcho has gone from being a research-focused company to today being a medical technology product development company, with both a clinical and commercial focus.

The number of persons affected by rectal cancer globally is expected to increase by 50 percent from 2020 to 2030. This is largely due to an increase in life expectancy and the fact that the Western lifestyle is spreading throughout the world. Today, established clinical practice for mapping the spread of rectal cancer to the lymph nodes is insufficient, which means that the majority of patients with early rectal cancer undergo major risky interventions unnecessarily.

NanoEcho is developing a diagnostic method to map any spread of rectal cancer to nearby lymph nodes. This is an important marker of how advanced the cancer is and enables an optimal individually adapted treatment. The patented technology uses a magnetic field and iron oxide-based nanoparticles together with modern ultrasound technology, in a completely new way. Given the global increase in rectal cancer cases, combined with the introduction of screening, the method has a large market potential.

Today, the majority of patients diagnosed with early rectal cancer are recommended to undergo an extensive and risky surgical procedure. Published research has shown that in 9 cases out of 10, a significantly smaller intervention would have been sufficient. With NanoEcho’s improved diagnostics, there is potential for healthcare to optimise its resources, while improving patients’ quality of life. Overall, this means large health economic gains.

NanoEcho’s management consists of a team with extensive experience and knowledge in medical technology and the commercialisation of medical devices, a team with documented experience in taking products from idea stage to commercially viable launches. The company has in a short time gone from being a research company to becoming a medical technology product development company with a clinical and commercial focus.